No products in the cart.
Pre-made Enuzovimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-665
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Enuzovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.Enuzovimab is an?anti-SARS-CoV-2 recombinant antibody engineered with specific sequences?identified from the B cells of a COVID-19 convalescent patient. The antibody binds to the viral spike protein with high affinity and has demonstrated potent neutralization of live virus infections in vitro and in vivo.
| Products Name (INN Index) | Pre-Made Enuzovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
|---|---|
| INN Name | Enuzovimab |
| Target | SARS-CoV-2 Spike RBD |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | 7cjf:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2021 |
| Year Recommended | NA |
| Companies | ABL Bio,HiFiBiO Therapeutics |
| Conditions Approved | NA |
| Conditions Active | COVID-19 |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | SARS-CoV-2 Spike RBD |
| Package |
Previous slide
Next slide
